Novartis: more positive data in acute leukaemia.
(CercleFinance.com) - Data from a phase III trial reinforced the efficacy and safety of Rydapt in patients with acute myeloid leukemia, a rare and aggressive cancer of the blood and bone marrow, Novartis said last Friday.
The full results from the clinical trial - published in The New England Journal of Medicine (NEJM) - show that patients aged 18-59 years treated with Rydapt, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, experienced significant improvement in overall survival with a 22% reduction in the risk of death compared with chemotherapy plus placebo.
The median event-free survival was 8.2 months in the Rydapt arm and 3 months in the placebo arm.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The full results from the clinical trial - published in The New England Journal of Medicine (NEJM) - show that patients aged 18-59 years treated with Rydapt, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, experienced significant improvement in overall survival with a 22% reduction in the risk of death compared with chemotherapy plus placebo.
The median event-free survival was 8.2 months in the Rydapt arm and 3 months in the placebo arm.
Copyright (c) 2017 CercleFinance.com. All rights reserved.